Search Results - jeffrey+rothstein

3 Results

Sort By:

Antisense oligonucleotide therapy and biomarker assay for C9ORF72 hexanucleotide expansion disorders

Therapy to Treat and Assay to Monitor Neurodegenerative Disease JHU REF: [C12195]Invention novelty: This technology is the use of antisense oligonucleotides (ASO) as a therapeutic for specific neurodegenerative diseases. The technology could also be used in development of a biomarker assay to monitor the efficacy of the ASO therapy. Value Proposition: Current...

Published: 6/27/2024 | Inventor(s): Christopher Donnelly, C. Bennett, Susan Freier, Rita Sattler, Jeffrey Rothstein

Keywords(s): Amyotrophic Lateral Sclerosis, Assay, Biologics, Clinical Diagnostics, CNS and Neurological Disorders, Dementia, Disease Indication, In Vitro Diagnostics, Neurodegeneration, Nucleic Acid, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Dementia, Clinical and Disease Specializations > Neurology > Neurodegeneration

Stimulation of Dendrite Growth and Spine Formation by Norrin and LGR6: A Target for Therapy in CNS Injury and Degeneration

Unmet NeedAstroglial dysfunction is associated with the development of numerous central nervous system (CNS) diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and Huntington’s disease (HD). Astroglia are the homeostatic cells of the central nervous system and play key roles in the development and support of neuronal...

Published: 6/27/2024 | Inventor(s): Sean Miller, Jeffrey Rothstein

Keywords(s): Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Biologics, CNS and Neurological Disorders, Dementia, Disease Indication, Huntington's Disease, Parkinson's Disease, Protein, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Dementia, Technology Classifications > Therapeutic Modalities > Proteins, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Neurology > Huntington's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease

Hybridoma Clone G6

C10552: Hybridoma Secreting Anti-Excitatory Amino Acid Transporter 2 (EAAT2) AntibodyNovelty: Hybridoma cell line that secretes monoclonal antibody to GLT1/EAAT2 protein.Value Proposition: Mutations or decreased expression of the GLT1/EAAT2 protein are associated with amyotrophic lateral sclerosis and thus the detection of protein can be used as an...

Published: 6/27/2024 | Inventor(s): Jeffrey Rothstein

Keywords(s): Amyotrophic Lateral Sclerosis, Basic Research Biomarker, Cell Lines, Cell Model, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, Human Cell Lines, Hybridomas, In Vitro Research Tool, Translational Research Biomarker

Category(s): Technology Classifications > Research Tools > Antibodies, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools, Clinical and Disease Specializations > Rare Diseases, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Technology Classifications > Research Tools > Human Cell Lines